Voyager Therapeutics Share Holder Equity 2014-2022 | VYGR

Voyager Therapeutics share holder equity from 2014 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
Voyager Therapeutics Annual Share Holder Equity
(Millions of US $)
2021 $95
2020 $154
2019 $100
2018 $46
2017 $134
2016 $136
2015 $169
2014 $1
2013 $-4
Voyager Therapeutics Quarterly Share Holder Equity
(Millions of US $)
2022-03-31 $76
2021-12-31 $95
2021-09-30 $87
2021-06-30 $111
2021-03-31 $136
2020-12-31 $154
2020-09-30 $166
2020-06-30 $77
2020-03-31 $80
2019-12-31 $100
2019-09-30 $108
2019-06-30 $118
2019-03-31 $101
2018-12-31 $46
2018-09-30 $66
2018-06-30 $82
2018-03-31 $98
2017-12-31 $134
2017-09-30 $85
2017-06-30 $105
2017-03-31 $123
2016-12-31 $136
2016-09-30 $149
2016-06-30 $156
2016-03-31 $164
2015-12-31 $169
2015-09-30 $102
2015-06-30 $0
2015-03-31 $0
2014-12-31 $1
2014-09-30 $0
2014-06-30
2014-03-31
2013-12-31 $-4
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.233B $0.037B
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00